Observed performance metrics in laboratory models
Observed performance metrics in laboratory models
ACP-105 is typically administered at a dose of 10 mg once daily for research applications, with one capsule per 24 hours being the standard.
Consistency in dosing and alignment with structured protocols can support optimal research outcomes.
ACP-105 is typically administered at a dose of 10 mg once daily for research applications, with one capsule per 24 hours being the standard.
Consistency in dosing and alignment with structured protocols can support optimal research outcomes.
Free shipping worldwide on all orders. This includes delivery to APO, DPO & FPO addresses.
Domestic: 5-7 business days.
International: 10-14 business days.
No express shipping due to timing inconsistencies from couriers.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.
Block quote
Ordered list
Unordered list
Bold text
Emphasis
Superscript
Subscript
Research summary on ACP-105
Motor Coordination & Neuroprotection
ACP-105 is a Selective Androgen Receptor Modulator (SARM) — researched for its anabolic effects inmuscle and bone.
In research settings, it has been shown to:
✔ Promote muscle growth in wasting conditions.
✔ Support bone density maintenance
✔ Enhance physical performance.
🦾 MUSCLE PRESERVATION:
ACP-105 has shown potential to prevent muscle loss during periods of disuse
🛠️ BONE SUPPORT:
Improves bone mineral density in preclinical models.
🏅 ATHLETIC PERFORMANCE:
May increase exercise capacity and recovery rates
1. Synthesis, structure–activity relationships, and characterization of novel nonsteroidal and selective androgen receptor modulators
https://pubmed.ncbi.nlm.nih.gov/19856921/
2. Effects of the SARM ACP-105 on rotorod performance and cued fear conditioning in (irradiated) female mice
https://pubmed.ncbi.nlm.nih.gov/21219889/
3. Nonsteroidal SARMs and selective estrogen receptor β agonists moderate cognitive deficits and amyloid-β levels in a mouse model of Alzheimer’s diseas
https://pubmed.ncbi.nlm.nih.gov/24881457/
4. Identification of equine in vitro metabolites of SARMs for doping control
Explore the best stack options.